Literature DB >> 12955213

[Magnetic resonance imaging in clinical diagnosis of dementia].

J Schröder1, J Pantel, P Schönknecht, M Essig.   

Abstract

Dementing disorders belong to the most frequent neuropsychiatric diseases of the elderly population with prevalence rates of 5% in the 75 year old, but more than 10% in subjects older than 80 years. It is broadly accepted that the dementias are not caused by a single etiological factor but are attributed to a variety of different disease processes that affect the brain either directly or indirectly. According to pathoanatomic studies, two thirds of all dementias are caused by Alzheimer's disease (AD). Early recognition and differential diagnosis, which represent an important prerequisite for an optimized therapy, can be facilitated considerably by neuroimaging as well as by molecular biological findings. Therapeutic approaches include general medical management, psychosocial interventions as well as pharmacotherapy of cognitive and non-cognitive deficits. In general, early intervention using a combination of different therapeutic measures is recommended. In future, structural and functional neuroimaging might not only be used for diagnostic purposes but also to objectify and monitor the effect of treatment on relevant brain structures

Entities:  

Mesh:

Year:  2003        PMID: 12955213     DOI: 10.1007/s00117-003-0924-5

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  16 in total

1.  Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls.

Authors:  Peter Schönknecht; Dieter Lütjohann; Johannes Pantel; Habertus Bardenheuer; Tobias Hartmann; Klaus von Bergmann; Konrad Beyreuther; Johannes Schröder
Journal:  Neurosci Lett       Date:  2002-05-10       Impact factor: 3.046

2.  Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

Authors:  K Herholz; E Salmon; D Perani; J C Baron; V Holthoff; L Frölich; P Schönknecht; K Ito; R Mielke; E Kalbe; G Zündorf; X Delbeuck; O Pelati; D Anchisi; F Fazio; N Kerrouche; B Desgranges; F Eustache; B Beuthien-Baumann; C Menzel; J Schröder; T Kato; Y Arahata; M Henze; W D Heiss
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

3.  Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression.

Authors:  M Jensen; J Schröder; M Blomberg; B Engvall; J Pantel; N Ida; H Basun; L O Wahlund; E Werle; M Jauss; K Beyreuther; L Lannfelt; T Hartmann
Journal:  Ann Neurol       Date:  1999-04       Impact factor: 10.422

4.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery.

Authors:  K A Welsh; N Butters; R C Mohs; D Beekly; S Edland; G Fillenbaum; A Heyman
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

5.  Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging.

Authors:  J Schröder; J Pantel; N Ida; M Essig; T Hartmann; M V Knopp; L R Schad; R Sandbrink; H Sauer; C L Masters; K Beyreuther
Journal:  Mol Psychiatry       Date:  1997 Oct-Nov       Impact factor: 15.992

Review 6.  Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.

Authors:  Jeffrey L Cummings
Journal:  Am J Geriatr Psychiatry       Date:  2003 Mar-Apr       Impact factor: 4.105

7.  Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease.

Authors:  Peter Schönknecht; Johannes Pantel; Aoife Hunt; Martin Volkmann; Katharina Buerger; Harald Hampel; Johannes Schröder
Journal:  Neurosci Lett       Date:  2003-03-20       Impact factor: 3.046

8.  Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy.

Authors:  Peter Schönknecht; Johannes Pantel; Tobias Hartmann; Egon Werle; Martin Volkmann; Marco Essig; Michael Amann; Nadja Zanabili; Hubertus Bardenheuer; Aoife Hunt; Johannes Schröder
Journal:  Psychiatry Res       Date:  2003-10-15       Impact factor: 3.222

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  Parahippocampal volume deficits in subjects with aging-associated cognitive decline.

Authors:  Johannes Pantel; Benita Kratz; Marco Essig; Johannes Schröder
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

View more
  1 in total

1.  [Diagnostic value of multislice perfusion CT in dementia patients].

Authors:  F Streitparth; G Wieners; A Kämena; R J Schröder; H Stiepani; T Kokocinski; R Röttgen; E Steinhagen-Thiessen; R Lenzen-Grossimlimghaus; N Hidajat
Journal:  Radiologe       Date:  2008-02       Impact factor: 0.635

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.